Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | PRNP | P04156 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | PARP1 | P09874 | 1/20 | 0.50 |
| ▸ | MMP12 | P39900 | 1/20 | 0.44 |
| ▸ | AHR | P35869 | 1/20 | 0.42 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | DRD4 | P21917 | 3/20 | 0.40 |
| ▸ | DRD3 | P35462 | 3/20 | 0.40 |
| ▸ | NOS1 | P29475 | 1/20 | 0.39 |
| ▸ | AXL | P30530 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 2/20 | 0.39 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL28898050 | 0.98 | MEN1 (0.50) | MEN1KMT2AALDH1A1PRNPMAPT | |
| SCHEMBL20878376 | 0.77 | BRD4 (0.56) | MEN1KMT2AALDH1A1PRNPMAPT | |
| SCHEMBL3171067 | 0.76 | PARP1 (0.52) | MEN1KMT2AALDH1A1PRNPMAPT | |
| SCHEMBL1261706 | 0.74 | PARP1 (0.55) | MEN1KMT2AALDH1A1PRNPMAPT | |
| SCHEMBL196738 | 0.74 | PARP1 (0.56) | MEN1KMT2AALDH1A1PRNPMAPT | |
| SCHEMBL13857864 | 0.74 | PARP1 (0.50) | MEN1KMT2AALDH1A1PRNPMAPT | |
| SCHEMBL2884811 | 0.74 | PARP1 (0.56) | MEN1KMT2AALDH1A1PRNPMAPT | |
| SCHEMBL3157571 | 0.74 | PARP1 (0.50) | MEN1KMT2AALDH1A1PRNPMAPT | |
| SCHEMBL8667 | 0.74 | PARP1 (0.56) | MEN1KMT2AALDH1A1PRNPMAPT | |
| SCHEMBL312427 | 0.74 | PARP1 (0.56) | MEN1KMT2AALDH1A1PRNPMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 285 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260109670-A1 | METHOD FOR ARYL DEBROMINATION AND ACYLATION OF BROMINATED BENZO-FUSED NITROGEN HETEROCYCLE | Shanghai OuChem Bio-Technology Co., LTD (CN) | 2026-04-23 | — | — | US | claimed |
| WO-2011033235-A1 | COMPOSITE MATERIAL COMPRISING AN ORGANIC-INORGANIC MATERIAL, PREPARATION PROCESS, AND USES | TREDI (FR) | 2011-03-24 | — | — | WO | claimed |
| CN-117050075-B | Biaryl ring BET inhibitor and synthetic method and application thereof | CHINA PHARMACEUTICAL UNIVERSITY (CN) | 2026-05-26 | — | — | CN | disclosed |
| US-20260137697-A1 | THIAZOLO[5,4-D]PYRIMIDINE COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF | UNIV DE MONTREAL (CA) | 2026-05-21 | — | — | US | disclosed |
| US-20260132147-A1 | BAX INHIBITORS AND USES THEREOF | CASE WESTERN RESERVE UNIV (US) | 2026-05-14 | — | — | US | disclosed |
| US-12622893-B2 | Alpha2 adrenergic agonist codrugs conjugated with muscarinic agonist drugs | ADS THERAPEUTICS LLC | 2026-05-12 | — | — | US | disclosed |
| WO-2026090348-A1 | THE USE OF SON OF SEVENLESS (SOS) INHIBITOR COMPOUNDS SUCH AS 7-SUBSTITUTED BENZOFURANS TO TREAT CANCER | Mirati Therapeutics, Inc. (US) | 2026-04-30 | — | — | WO | disclosed |
| US-20260109670-A1 | METHOD FOR ARYL DEBROMINATION AND ACYLATION OF BROMINATED BENZO-FUSED NITROGEN HETEROCYCLE | Shanghai OuChem Bio-Technology Co., LTD (CN) | 2026-04-23 | — | — | US | disclosed |
| US-20260078117-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS INC (US) | 2026-03-19 | — | — | US | disclosed |
| US-12565490-B2 | Inhibitors of Receptor Interacting Protein Kinase I for the treatment of disease | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2026-03-03 | — | — | US | disclosed |
| US-20250387397-A1 | SUBSTITUTED AMINO TRIAZOLOPYRIMIDINE AND AMINO TRIAZOLOPYRAZINE ADENOSINE RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE | MERCK SHARP & DOHME LLC (US) | 2025-12-25 | — | — | US | disclosed |
| US-20050282820-A1 | Processes for preparing gonadotropin releasing hormone receptor antagonists | WYETH (US) | 2005-12-22 | — | — | US | disclosed |
| US-20040192749-A1 | 1-Aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands | WYETH | 2004-09-30 | — | — | US | disclosed |
| US-20040132741-A1 | 1-Aryl-or 1-alkylsulfonyl-heterocyclybenzoles as 5-hydroxytryptamine-6 ligands | WYETH | 2004-07-08 | — | — | US | disclosed |
| US-20040087595-A1 | 1-aryl- or 1-alkylsulfony-heterocyclybenzazoles as 5-hydroxytryptamine-6 ligands | WYETH | 2004-05-06 | — | — | US | disclosed |
| EP-1343756-A2 | 1-ARYL- OR 1-ALKYLSULFONYL-HETEROCYCLYLBENZAZOLES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | Wyeth (US) | 2003-09-17 | — | — | EP | disclosed |
| US-20020115670-A1 | 1-Aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands | AMERICAN HOME PRODUCTS CORPORATION | 2002-08-22 | — | — | US | disclosed |
| WO-2002036562-A2 | 1-ARYL- OR 1-ALKYLSULFONYL-HETEROCYCLYLBENZAZOLES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | WYETH (US) | 2002-05-10 | — | — | WO | disclosed |
| US-3988155-A | CYANINE SENSITIZING DYES | FUJI PHOTO FILM CO., LTD. (JA) | 1976-10-26 | — | — | US | disclosed |
| US-3985563-A | Silver halide photographic emulsion | FUJI PHOTO FILM CO., LTD. (JA) | 1976-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260132147-A1 | BAX INHIBITORS AND USES THEREOF | BAX, BCL2, BAK1 | MEN1 3361/4885KMT2A 4854/4885ALDH1A1 4585/4885 |
| US-20050282820-A1 | Processes for preparing gonadotropin releasing hormone receptor antagonists | GNRHR, GHRHR, LHCGR | MEN1 534/4885KMT2A 2102/4885ALDH1A1 4797/4885 |
| US-20260137697-A1 | THIAZOLO[5,4-D]PYRIMIDINE COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF | NRAS, KRAS, BRAF | MEN1 3244/4885KMT2A 3348/4885ALDH1A1 2369/4885 |
| US-20040192749-A1 | 1-Aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands | HTR6, HTR1A, HTR1B | MEN1 3229/4885KMT2A 2393/4885ALDH1A1 474/4885 |
| US-20260109670-A1 | METHOD FOR ARYL DEBROMINATION AND ACYLATION OF BROMINATED BENZO-FUSED NITROGEN HETEROCYCLE | NAT1, AADAC, NAA15 | MEN1 1962/4885KMT2A 1608/4885ALDH1A1 1084/4885 |
| US-12622893-B2 | Alpha2 adrenergic agonist codrugs conjugated with muscarinic agonist drugs | ADRB2, ADRA1D, ADRB1 | MEN1 2900/4885KMT2A 1560/4885ALDH1A1 733/4885 |
| US-20040132741-A1 | 1-Aryl-or 1-alkylsulfonyl-heterocyclybenzoles as 5-hydroxytryptamine-6 ligands | HTR6, HTR1B, HTR1A | MEN1 2841/4885KMT2A 2733/4885ALDH1A1 498/4885 |
| US-20020115670-A1 | 1-Aryl- or 1-alkylsulfonyl-heterocyclylbenzazoles as 5-hydroxytryptamine-6 ligands | HTR6, HTR1A, HTR1B | MEN1 3229/4885KMT2A 2393/4885ALDH1A1 474/4885 |
| US-20260078117-A1 | COMPOUNDS AND METHODS OF USE | NR3C2, ADRA1A, CNR1 | MEN1 1978/4885KMT2A 3362/4885ALDH1A1 100/4885 |
| US-12565490-B2 | Inhibitors of Receptor Interacting Protein Kinase I for the treatment of disease | RIPK1, RIPK4, RIPK2 | MEN1 4734/4885KMT2A 3522/4885ALDH1A1 4643/4885 |
| US-20250387397-A1 | SUBSTITUTED AMINO TRIAZOLOPYRIMIDINE AND AMINO TRIAZOLOPYRAZINE ADENOSINE RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE | ADORA2A, ADORA2B, ADORA1 | MEN1 4466/4885KMT2A 2228/4885ALDH1A1 291/4885 |
| US-20040087595-A1 | 1-aryl- or 1-alkylsulfony-heterocyclybenzazoles as 5-hydroxytryptamine-6 ligands | HTR6, HTR1B, HTR1A | MEN1 2580/4885KMT2A 3417/4885ALDH1A1 616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.